MARKET

BDTX

BDTX

Black Diamond Therapeutics, Inc.
NASDAQ
1.595
-0.265
-14.25%
Pre Market: 1.742 +0.147 +9.22% 04:28 11/11 EST
OPEN
1.900
PREV CLOSE
1.860
HIGH
1.910
LOW
1.580
VOLUME
85
TURNOVER
0
52 WEEK HIGH
4.940
52 WEEK LOW
1.580
MARKET CAP
91.64M
P/E (TTM)
-2.1415
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Black Diamond Therapeutics (BDTX) and CalciMedica (CALC)
TipRanks · 13h ago
Why Is Black Diamond Therapeutics Stock Soaring Tuesday?
Benzinga · 15h ago
Black Diamond Therapeutics’ silevertinib shows efficacy in Phase 2 trial
TipRanks · 17h ago
Black Diamond Therapeutics GAAP EPS of -$0.17
Seeking Alpha · 18h ago
Black Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares Rise
NASDAQ · 22h ago
Black Diamond Therapeutics Reports Updated Phase 2 Silevertinib Data, FDA End-Of-Phase 2 Feedback, Supporting Pivotal Development In All 1L EGFR-NCM NSCLC Patients With Potential For Accelerated Approval Based On CNS-ORR
Benzinga · 22h ago
*Black Diamond Theraptcs 3Q Loss/Shr 17c >BDTX
Dow Jones · 23h ago
Press Release: Black Diamond Therapeutics -2-
Dow Jones · 23h ago
More
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Webull offers Black Diamond Therapeutics Inc stock information, including NASDAQ: BDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDTX stock methods without spending real money on the virtual paper trading platform.